Our Patients are Less Depressed-But More Empty

How depression changes with time, sex, and substances

Photo by Gianfranco Grenar on Unsplash

Our Patients are Less Depressed-But More Empty

In recent years, an increasingly common clinical pattern has emerged across both outpatient and inpatient settings: many patients no longer present with the classic “deeply sad” and tearful depressive picture that once dominated diagnostic frameworks. Instead, many describe a pervasive sense of emptiness, an anhedonic inability to enjoy previously meaningful activities, and a lack of motivation—yet they score in the mild to moderate range on traditional measures of depression. This state, often dismissed as subthreshold or residual dysthymia, may be better understood through the lens of anhedonia—the diminished capacity to experience pleasure—and its broader impact on quality of life.

Anhedonia is not new to psychiatry. But its clinical prominence and presentation frequency have grown. Contemporary research confirms that anhedonia is a core symptom domain of major depressive disorder (MDD), profoundly impacting functional outcomes and quality of life, even when other mood symptoms have improved. Meta-analytic evidence shows a statistically significant correlation between anhedonia severity and both lower health-related quality of life (r = −0.41) and greater functional impairment (r = 0.39) in adults with MDD, irrespective of mood symptom severity. In other words, anhedonia alone is a pretty reliable predictor of depression severity.

This shifting landscape challenges traditional diagnostic paradigms. Whereas depressed mood and affective flattening once served as primary clinical anchors, many patients today describe their chief complaint as “feeling flat,” “nothing feels worthwhile,” or “I’m not sad so much as uninterested in life.” These complaints reflect more than semantic nuance: they point to reward processing deficits, where pleasure anticipation and engagement are blunted even in the absence of sad mood.

In my clinical experience, these presentations are more commonly seen in men than women, which might explain why male depression tends to be underdiagnosed. Anhedonia is also a core feature found in substance use disorders- both in patients with active use and patients who are in early recovery. These patients are still experiencing a dopamine deficit due to substance use that results in prominent anhedonia. This at least partly explains why depression is so common in folks suffering with substance use disorders, and why the first year in recovery can be so challenging.

Clinically, this translates into a common but under-recognized pattern: patients whose standardized depression scores do not reach thresholds for “moderate” or “severe” depression yet experience a significant impairment in subjective well-being and engagement with life. Standard symptom counts (e.g., PHQ-9) may undercapture these experiences, as they emphasize affective and somatic complaints while anhedonia often manifests in reduced positive affect rather than heightened negative affect. In other words, the PHQ-9 over measures negative symptoms and undermeasures positive symptoms. Emerging research confirms that these traditional diagnostic tools may underestimate anhedonic burden, contributing to under-recognition and under-treatment.

In practice, overlooking this dimension carries real consequences. Anhedonia is associated with poorer treatment outcomes, lower work productivity, and greater healthcare utilization, even among patients whose dysphoria has remitted. Moreover, anhedonic symptoms often persist after remission of other depressive features and may predict depression recurrence if left unresolved.

The clinical imperative is twofold. First, we must routinely assess hedonic capacity and reward responsiveness in our evaluations—not as ancillary features but as central determinants of patient suffering and functional disability, especially in our male patients and our patients suffering from substance use disorders. Second, we should consider treatment strategies that specifically target anhedonic processes, whether through tailored psychotherapeutic approaches (e.g., behavioral activation and positive affect interventions), novel pharmacologic agents that preferentially engage dopaminergic and reward circuits (think Wellbutrin), or emerging neuromodulatory interventional techniques like TMS.

Ultimately, recognizing that patients today may be “less depressed but emptier” is not a semantic exercise. It reflects a deeper understanding of how mood, reward, meaning, engagement, and fulfillment intersect in contemporary psychiatric practice. It reflects how mood presentations can differ based on sex and substances. By centering anhedonia in our clinical thinking, we can better align our assessments and interventions with the lived experiences of the patients who seek our care—moving beyond simple DSMV symptom counts to restore vitality, purpose, and pleasure in life.

-Lauren Grawert

TAGS: #laurengrawert #advancedpracticepartners #wisconsin #mentalwellness #2025 #2026 #health #oped #wisdom #hipaa #psychiatrists #pmhnp #therapists #psychology #medical

LINKS: advancedpracticepartners.com | The White Coat Warrior  | WIKI LINKEDIN | Lauren Grawert | Robert Glenn | Jon Snipes

© 2026